Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia (Q47398807)

15 January 2018

title

Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia (English)

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(03)00521-8

29 March 2024

1 reference

1 reference

0 references

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(03)00521-8

29 March 2024

author name string

Jan Törling

1

1 reference

15 January 2018

Jonas Hedlund

2

1 reference

15 January 2018

Helle Bossen Konradsen

3

1 reference

15 January 2018

Ake Ortqvist

4

1 reference

15 January 2018

language of work or name

English

0 references

publication date

1 December 2003

1 reference

15 January 2018

8 December 2003

1 reference

National Center for Biotechnology Information

PubMed ID

14604576

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14604576

full work available at URL

29 March 2024

https://api.elsevier.com/content/article/PII:S0264410X03005218?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(03)00521-8

https://api.elsevier.com/content/article/PII:S0264410X03005218?httpAccept=text/plain

29 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(03)00521-8

29 March 2024

1 reference

15 January 2018

volume

22

1 reference

15 January 2018

issue

1

1 reference

15 January 2018

page(s)

96-103

1 reference

15 January 2018

The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900521-8

7 January 2021

Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900521-8

7 January 2021

Considerations for Formulating the Second-Generation Pneumococcal Capsular Polysaccharide Vaccine with Emphasis on the Cross-Reactive Types Within Groups

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900521-8

7 January 2021

Specific immunoglobulin-class antibody responses in the elderly before and after 14-valent pneumococcal vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900521-8

7 January 2021

Magnitude, duration, quality, and function of pneumococcal vaccine responses in elderly adults

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900521-8

7 January 2021

Determination of antibody responses of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900521-8

7 January 2021

The antibody responses to pneumococcal capsular polysaccharides in aged individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900521-8

7 January 2021

Immune response of elderly adults to pneumococcus: variation by age, sex, and functional impairment

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900521-8

7 January 2021

Quantity and avidity of pneumococcal antibodies before and up to five years after pneumococcal vaccination of elderly persons

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900521-8

7 January 2021

Pneumococcal polysaccharide vaccine in young adults and older bronchitics: determination of IgG responses by ELISA and the effect of adsorption of serum with non-type-specific cell wall polysaccharide

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900521-8

7 January 2021

Antibody response to pneumococcal capsular polysaccharide vaccine in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900521-8

7 January 2021

The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900521-8

7 January 2021

Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900521-8

7 January 2021

The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900521-8

7 January 2021

Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in elderly people: a 1-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900521-8

7 January 2021

Effectiveness of pneumococcal polysaccharide vaccine in older adults

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900521-8

7 January 2021

Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900521-8

7 January 2021

Antibody response of pneumococcal vaccine: need for booster dosing?

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900521-8

7 January 2021

Persistence of antibodies to pneumococcal capsular polysaccharide vaccine in the elderly.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900521-8

7 January 2021

Safety of revaccination with pneumococcal polysaccharide vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900521-8

7 January 2021

Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900521-8

7 January 2021

Recurrence of pneumonia in relation to the antibody response after pneumococcal vaccination in middle-aged and elderly adults

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900521-8

7 January 2021

Revaccination with pneumococcal vaccine of elderly persons 6 years after primary vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900521-8

7 January 2021

Antibody to Capsular Polysaccharides of Streptococcus pneumoniae: Prevalence, Persistence, and Response to Revaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900521-8

7 January 2021

A Multiplexed Fluorescent Microsphere Immunoassay for Antibodies to Pneumococcal Capsular Polysaccharides

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900521-8

7 January 2021

Rethinking recommendations for use of pneumococcal vaccines in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900521-8

7 January 2021

A longitudinal study of class and subclass antibody response to pneumococcal vaccination in splenectomized individuals with special reference to patients with Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900521-8

7 January 2021

Efficacy and safety of pneumococcal revaccination after splenectomy for trauma

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900521-8

7 January 2021

Associations of prevaccination antibody levels with adverse reactions to pneumococcal and influenza vaccines administered simultaneously in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900521-8

7 January 2021

Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay

31

1 reference

https://api.crossref.org/works/10.1016/S0264-410X(03)00521-8

29 March 2024

Identifiers

1 reference

15 January 2018

PubMed ID

14604576

1 reference

15 January 2018